Skip to Main Content

Yale SPORE in Lung Cancer News

Yale Cancer Center Study Characterizes Link Between Drug Resistance and Central Nervous System Relapse

A new study from Yale Cancer Center characterizes the functional link between drug resistance and central nervous system (CNS) relapse. The findings from a study led by Don Nguyen, PhD, BS, Associate Professor of Pathology and Medicine (Medical Oncology) and Assistant Yale Cancer Center Director for Research Development, were recently published in the journal Nature Communications.

Read more
  • 4 longtime biostatistics professors look back on their years at YSPH

    The Yale School of Public Health’s Department of Biostatistics is experiencing the end of an era. Four senior faculty representing more than 120 years of teaching and research experience have either recently retired or soon will retire. The work of these distinguished leaders in biostatistics at Yale – Robert Makuch, Theodore Holford, Peter Peduzzi, and Daniel Zelterman - helped define the department as it exists today.

    Read more
  • Why Some Lung Tumors Respond Better to Targeted Therapies Than Others

    In a new study, Yale Cancer Center researchers found molecular explanations for why some lung tumors respond better to certain drugs than others. The research should help improve drug selection for lung cancer patients with different mutations in the EGF receptor, using a precision medicine approach to treatment.

    Read more
  • ADAURA Update: Osimertinib Benefit in Early NSCLC Sustained

    An updated analysis of the phase III ADAURA trial revealed a median disease-free survival (DFS) of 5.5 years for early-stage, EGFR-positive non-small cell lung cancer (NSCLC) patients who received osimertinib (Tagrisso) in the postoperative setting, with nearly three in four patients treated with the adjuvant therapy free of disease at 4 years.

    Source: MED Page Today
    Read more
  • ADAURA Trial Results Provide New Hope for Patients with Early-Stage Non-Small Cell Lung Cancer

    Newly released results from the Phase III ADAURA trial reveal that osimertinib yielded a 5.5-year median disease-free survival in the post-surgical treatment of patients with EGFR-mutated lung cancer, and nearly three in four patients treated with adjuvant osimertinib were disease-free at four years. The new results also indicated that the use of osimertinib reduced the risk of disease recurrence in the brain and spinal cord. The results from the study were presented today at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.

    Read more
  • How Do Patients Feel About Using AI in Health Care?

    New research from Yale Cancer Center provides a new understanding of patients’ views of artificial intelligence (AI) in healthcare. While comfort level varied by clinical application, most respondents had positive views about AI’s ability to improve care. Concerns surfaced when potential for misdiagnosis, privacy breaches, reduced time with clinicians, and increased costs were discussed.

    Read more